Genonto Seeks FDA Approval For 10 Minute COVID-19 Test For Point Of Care Use
The most effective way to flatten the curve in the spread of the COVID-19 disease is early detection and containment at the point of care. Genonto's new RapidTest10 slashes that waiting time from days to mere minutes.
By: In Focus Brands
Another issue is that a person is often tested only after they exhibit symptoms; in some cases virus carriers are asymptomatic. By the time they are tested, they may have unwittingly exposed others to the virus.
Genonto, the market leader in genetic sequencing to detect genes linked to opioid dependency and other dependence diseases now has available an easy, accurate, rapid result COVID-19 test kit, the Genonto RapidTest10, that can render results in only 10 minutes.
The Genonto RapidTest10 is an easy-to-use method that uses whole blood, serum or plasma for testing and needs just a drop of blood from a finger stick as a sample. Unlike expensive, lengthy testing methods that require a laboratory, the Genonto RapidTest10 is a point of care (POC) cost-effective method to detect and diagnose COVID-19 disease. Not only does it reduce the burden on the healthcare workforce, but it also minimizes exposure for healthcare staff.
Genonto CEO Phillip Clifford notes; "History has shown that periods of extreme hardship are often the catalyst for the development of life-saving innovation - this is such a time. The Genonto RapidTest10 levels the field so that the presence of the COVID-19 virus can quickly be confirmed in more people - helping to accelerate flattening the curve."
Genonto is the leader in genetic sequencing to detect genes linked to opioid dependency and other dependence diseases. The platform uses a proprietary methodology to examine the whole exome (WES) for detecting the presence of those genes which indicate a person is at risk for developing addictions and dependencies, with the goal of preventative strategies.